STAT Expert Advantage
A Look at the Breast Cancer Landscape: An Expert’s Take on the Newly Approved Daiichi Sankyo Drug, ENHERTU, SGEN’s tucatinib, & the Role of IO therapy
A Look at the Breast Cancer Landscape: An Expert’s Take on the Newly Approved Daiichi Sankyo Drug, ENHERTU, SGEN’s tucatinib, & the Role of IO therapy
On national TV, Oprah endorsed the use of GLP-1 drugs like Wegovy and Ozempic for obesity. She didn’t present the whole picture.
A new gene therapy will cost $4.25 million. But the return, in this case, is babies who get to have childhoods, grow up and become…
The European Commission has opened an antitrust investigation to determine whether Zoetis, one of the largest purveyors of medicines for dogs and cats, breached EU…
Melissa Simon, known for work to promote health equity and reduce health disparities, named to 2024 STATUS List for achievements in education and advocacy.
STAT Breakthrough Summit West is one-day event designed to break down silos across health and medicine by bringing together leaders, entrepreneurs, policymakers, patient advocates —…
It’s time to acknowledge that a law intended to right an egregious wrong has become harmful — and change it. That’s the case for Medicaid’s…
Gut bacteria could play important role in IgA nephropathy, a rare and serious kidney autoimmune disease, study shows.
STATUS List 2024: Meet Steven Rosenberg, the cancer immunotherapy trailblazer behind Yescarta, a blood cancer therapy with more than $1 billion in sales.
CAR-T therapies have proved curative for some blood cancer patients, but their high prices have limited access in much of the world. The Brazilian government…
Multiple sclerosis went from an untreatable disease to a known, druggable condition in less than 40 years. Now a study finds subtypes that may benefit from…